Other safety alerts
|
| |
| Australia: Counterfeit Ozempic injection pens detected |
| |
The Therapeutic Goods Administration (TGA) announces that consumers and health professionals should be aware that counterfeit Ozempic-labelled products have been stopped at the Australian border. These injection pens may pose a serious risk to your health and should not be used. Though these products appear to be genuine Ozempic injections (semaglutide), the batch number on these 1mg injection pens - MPSD916 - has been confirmed as not a genuine batch number by Novo Nordisk, the manufacturer of Ozempic.
The products subject to this alert exhibited typographic inconsistencies in packaging compared to legitimate Ozempic products, including differences in spacing and bolding of the text.
Ozempic is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.
Consumers are advised to stop using counterfeit Ozempic pens including any marked with Batch number MPSD916 and take any remaining product to their local pharmacy for safe disposal.
Please refer to the following website in TGA for details:
http://www.tga.gov.au/news/safety-alerts/counterfeit-ozempic-injection-pens-detected
In Hong Kong, Ozempic Solution For Injection In 3.0ml Pre-filled Pen 1mg/dose (HK-66487) is a pharmaceutical product registered by Novo Nordisk Hong Kong Ltd. The product is a prescription-only medicine. The pack of the counterfeit Ozempic product mentioned in the above TGA’s announcement is different from the registered pack of the product in Hong Kong.
Ends/Thursday, Apr 3, 2025
Issued at HKT 17:15
|
| |
